image description
contact us
Name* Phone* E-mail* Message*

Captcha*



News Release

Oct 9, 2015

AdvaMed 2015: Advocating for Medical Innovation

In its ninth year, the AdvaMed Conference 2015 welcomed over 2,300 attendees from 900 international companies on October 5–7. Taking place in San Diego, a location boasting an abundance of opportunities for venture funding and healthcare research, this was the first occurrence of the conference on the US West Coast.

The San Diego Convention Center proved to be the perfect place to discover the latest medical innovations and technologies and gain insights into the key issues that have been driving the MedTech industry in recent years.

The MedTech industry has always been a major contributor to the global economy, and with the latest technology breakthroughs—including the rapid progress of the Internet of Things, cloud services, and wearables—the contribution of this industry can’t be underestimated.

According to the report presented at AdvaMed by Evaluate, a London-based life science market intelligence firm, the global MedTech market value will reach $477.5 billion by 2020, and worldwide MedTech R&D expenditure is expected to grow by 3.5% per year and reach $29.5 billion by the same year. This means that in the years to come, we will get to see even more life-changing innovations in the area of healthcare that will shape the global health ecosystem and help hospitals provide better care for more patients at lower costs.

Events like AdvaMed help us to gain perspective about the industry and assess our current position and the direction in which we should move. Once again, AdvaMed provided unparalleled opportunities to discuss the challenges that all market players currently face and will come across in the future. This year, these discussions mostly focused on the issues of digital health development, interoperability and integrated solutions, cybersecurity, and medical device regulation.

Within the frame of the conference and exhibition, there were almost 50 presentations of cutting-edge medical technologies, proving once again that the progress in this area is exploding and that all the numbers in the reports are not just words but represent saved lives and increased life expectancy. However, as it has been said many times in panel discussions, further innovations can only be made possible if the right policies are in place to encourage the next breakthroughs in medical technology.

Auriga is proud to be a part of this progress. The company has been providing software engineering services for the MedTech industry for over ten years, helping large medical device manufacturers and small innovative startups to create solutions that improve the lives of people all over the world.

AdvaMed is one of the key events in North America for the MedTech industry, and as we have done for the last few years, we jumped at the chance to present our software development services, knowledge, and expertise to the decision makers in this area. AdvaMed gave us an opportunity to discuss how we can help MedTech companies provide better healthcare services using pioneering innovations.

Marc Schlackman, Auriga’s Sales Director, shared his impressions of the event:

The AdvaMed 2015 exhibit floor provided more opportunities for both exhibitors and attendees to interact than in 2014.

Both exhibitor and attendee attendance was greater, and so were scheduled presentations and discussions. In addition to the CEO’s Unplugged Discussions held in the Exhibit Hall (same as last year), this year, the Innovation Showcase was added to the Exhibit Hall schedule. This provided a great opportunity to learn about startup companies working on cutting-edge technology and speak to their founders and technical leads.

This event enabled Auriga to not only rub shoulders with the giants in the industry but also meet the entrepreneurs who will be responsible for advancing the state of the art. Auriga is already planning to attend next year’s show, and we are pleased to continue being a part of this vibrant community.


Back to the list